Home > Insider Trading > Filing (0001415889-21-005014)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479419	Kala Pharmaceuticals Inc.	KALA	Pharmaceutical Preparations (2834)	270604595

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1710697	Hongming Chen	C/O Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 210 Watertown MA 02472	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-10-26	9,449	$1.80	225,566	No	4	S	Direct
Common Stock	Disposition	2021-10-27	21,051	$1.82	204,515	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 61,166 unvested RSUs.
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.84, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.